Developing Modular CRISPR-based RNPs to Edit Selected Cell Types In Vivo

Time: 11:00 am
day: Day Two


• Developing TAGE (Targeted Active Gene Editors), a new class of in vivo cell-targeting CRISPR RNP-based biologics
• Applying TAGE to expand the target space in immuno-oncology (IO), as well as for monogenic diseases therapies
• IO TAGE, targeting selected immune cells, reprogram the tumor microenvironment to facilitate a systemic anti-tumor response